Beril Aydin

Abstract Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies.

Beril Aydin In 1964, synthetic chemist Jerome Horwitz isolated a thymidine analog, azidothymidine, seeking anticancer activity. The therapeutic impact was not clear initially, but when NIH/NCI researchers demonstrated the potent anti-retroviral effects of azidothymidine, Burroughs Wellcome (now GSK) moved into trials quickly. On March 19, 1987, in a record-fast review, the FDA approved Retrovir (zidovudine), the first antiretroviral.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.